The SARS-CoV-2 spike protein receptor-binding domain (S-RBD) recognizes the human receptor angiotensin-converting enzyme 2 (ACE2), triggering fusion between the virus and host membranes.14,15 Therefore, chemicals that target the RBD could potentially block viral entry and thus be used as an effective COVID-19 therapy.14 This evidence concerns the gene ACE2 and COVID-19.